We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+14.65%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$331M
AUM Growth
+$11.7M
Cap. Flow
-$13.4M
Cap. Flow %
-4.06%
Top 10 Hldgs %
42.42%
Holding
75
New
12
Increased
16
Reduced
23
Closed
21

Top Buys

1
NVO
Novo Nordisk
NVO
+$14.7M
2
BPMC
Blueprint Medicines
BPMC
+$9.93M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.99M
4
JANX icon
Janux Therapeutics
JANX
+$6.09M
5
DYN icon
Dyne Therapeutics
DYN
+$3.98M

Top Sells

1
BHVN icon
Biohaven
BHVN
+$19.1M
2
VRDN icon
Viridian Therapeutics
VRDN
+$8.38M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$8.04M
4
SLNO
Soleno Therapeutics
SLNO
+$7.18M
5
PCVX icon
Vaxcyte
PCVX
+$6.31M

Sector Composition

1 Healthcare 83.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$29.6M 8.95%
+300,000
New +$29.5M
BHVN icon
2
CALL
Biohaven
BHVN
$2.28B
$17.4M 5.26%
+348,778
New +$13.6M
SRPT icon
3
Sarepta Therapeutics
SRPT
$1.82B
$15M 4.53%
120,000
+65,000
+118% +$8.99M
NVO
4
Novo Nordisk
NVO
$222B
$13.1M 3.96%
+110,000
New +$14.7M
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$12.9M 3.91%
140,000
+100,000
+250% +$9.93M
AXSM icon
6
Axsome Therapeutics
AXSM
$11.8B
$12.1M 3.66%
135,000
-15,000
-10% -$1.31M
TARS icon
7
Tarsus Pharmaceuticals
TARS
$2.58B
$11.5M 3.48%
350,000
+115,000
+49% +$3.23M
CATX icon
8
Perspective Therapeutics
CATX
$338M
$10M 3.02%
750,000
-175,000
-19% -$2.33M
CGON icon
9
CG Oncology
CGON
$6.34B
$9.43M 2.85%
250,000
-10,000
-4% -$351K
ROIV icon
10
Roivant Sciences
ROIV
$24.8B
$9.23M 2.79%
800,000
-200,000
-20% -$2.28M
PCVX icon
11
Vaxcyte
PCVX
$8.16B
$9.14M 2.76%
80,000
-70,000
-47% -$6.31M
VKTX icon
12
Viking Therapeutics
VKTX
$4.3B
$8.86M 2.68%
140,000
+45,000
+47% +$2.64M
SNDX icon
13
Syndax Pharmaceuticals
SNDX
$2.03B
$8.66M 2.62%
450,000
+100,000
+29% +$2.07M
JANX icon
14
Janux Therapeutics
JANX
$996M
$8.63M 2.61%
190,000
+140,000
+280% +$6.09M
ASND icon
15
Ascendis Pharma A/S
ASND
$17.3B
$7.84M 2.37%
52,500
-34,221
-39% -$4.62M
CRNX icon
16
Crinetics Pharmaceuticals
CRNX
$8.88B
$7.67M 2.32%
150,000
-90,000
-38% -$4.64M
SLNO
17
DELISTED
Soleno Therapeutics
SLNO
$7.57M 2.29%
150,000
-150,000
-50% -$7.18M
TGTX icon
18
TG Therapeutics
TGTX
$8.47B
$7.25M 2.19%
310,000
-190,000
-38% -$4.15M
RZLT icon
19
Rezolute
RZLT
$444M
$7.15M 2.16%
1,474,995
+53,494
+4% +$246K
PHAT icon
20
Phathom Pharmaceuticals
PHAT
$874M
$6.78M 2.05%
375,000
-225,000
-38% -$3.14M
MLTX icon
21
MoonLake Immunotherapeutics
MLTX
$1.64B
$6.47M 1.96%
128,411
-171,589
-57% -$8.04M
OLMA icon
22
Olema Pharmaceuticals
OLMA
$1.01B
$6.39M 1.93%
535,000
-15,000
-3% -$192K
IMVT icon
23
Immunovant
IMVT
$8.23B
$6.13M 1.85%
215,000
-45,000
-17% -$1.33M
INSM icon
24
Insmed
INSM
$23.5B
$5.47M 1.65%
75,000
+10,000
+15% +$738K
EWTX icon
25
Edgewise Therapeutics
EWTX
$4.3B
$5.2M 1.57%
+195,000
New +$3.88M
1
2 3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Ghost Tree Capital held 75 positions worth $331M, up 3.7% from $319M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ghost Tree Capital withdrew a net $13.4M in Q3 2024, closing 21 positions and reducing 23 holdings. Its most notable exit was Biohaven, an estimated $19.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 90% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Novo Nordisk worth $13.1M.

  • Ghost Tree Capital's largest Q3 2024 buy was Novo Nordisk: 110,000 shares worth $13.1M.
  • Ghost Tree Capital added most to Blueprint Medicines in Q3 2024, an estimated $9.93M increase.
  • Ghost Tree Capital's biggest Q3 2024 reduction was Viridian Therapeutics, cutting an estimated $8.38M.
  • Ghost Tree Capital fully exited Biohaven in Q3 2024, selling an estimated $19.1M.
  • Ghost Tree Capital's ten largest holdings make up 42% of its $331M portfolio in Q3 2024.
  • Ghost Tree Capital opened 12 new positions and closed 21 in Q3 2024.
  • Ghost Tree Capital's portfolio value rose 3.7% quarter-over-quarter to $331M.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.